j_fco-2023-0013_tab_004
| Age of diagnosis | Surgery | Adjuvant chemotherapy | Recurrence | Chemotherapy | Parp inhibitor | |
|---|---|---|---|---|---|---|
| 1 | 46 | 13/12/2019 | Taxol carbo | 07/2021 | Cisplat-gem | niraparib |
| 2 | 54 | 11/12/2018 | Taxol-carbo | 10/2021 | Cisplat-gem | niraparib |
| 3 | 43 | 20/11/2017 | Taxol-carbo | 08/2019 | Cisplat-gem | niraparib |
| 4 | 47 | 20/12/2018 | Taxol-carbo | 07/2020 | Cisplat-gem | niraparib |
Characteristics of the study population
| Characteristics | Results |
|---|---|
| Number of patients | 136 |
| Age | 59.93±15.77 |
| Body weight (6 months before) | 78.21±17.23 |
| BW now (at the study check point) | 72.76±15.35 |
| PG-SGA score | 10.41±5.6 |
| Gender male | 79(58.09%) |
| Tumor site | |
| Upper GI | 33(24.26%) |
| Lower GI | 30(22.06%) |
| Gynecology | 28(20.59%) |
| Thorax | 20(14.71%) |
| Urology | 10(7.35%) |
| Rare | 9(6.62%) |
| Head-Neck | 6(4.41%) |
| Metastasis | 101(74.26%) |
| Chemotherapy | 128(94.12%) |
| Radiotherapy | 28(20.59%) |
| Immunotherapy | 12(8.82%) |
| BW change during the last six months (in 3 scales) | |
| Loss | 91(66.91%) |
| Same | 15(11.03%) |
| Gain | 30(22.06%) |
| BW change during the last two weeks | |
| 1_Reduced | 53(39.26%) |
| 0_Same | 56(41.48%) |
| 2_Icreased | 26(19.26%) |
| Food consumption changes the last month | |
| 1_Reduced | 61(44.85%) |
| 0_Same | 45(33.09%) |
| 2_Increased | 30(22.06%) |
| PG-SGA score with cut off ≥9 (need for food intervention) | |
| <9 | 57(41.91%) |
| ≥9 | 79(58.09%) |
PG-SGA score with cut-off 9 in relation to cancer type
| PG-SGA score with cut off ≥9 | |||
|---|---|---|---|
| <9 | ≥9 | Total | |
| Upper GI | 15 (45.45%) | 18 (54.55%) | 33 |
| Lower GI | 19 (63.33%) | 11 (36.67%) | 30 |
| Gynecology | 15 (53.57%) | 13 (46.43%) | 28 |
| Thorax | 2 (10%) | 18 (90%) | 20 |
| Urology | 3 (30%) | 7 (70%) | 10 |
| Rare | 2 (22.22%) | 7 (77.78%) | 9 |
| Head-Neck | 1 (16.67%) | 5 (83.33%) | 6 |
| Total | 57 | 79 | 136 |
High Thrombotic risk factors_
| Neoplasm primary site | Incidence | Females | Age ≥65 | BMI ≥30 | Smoker (ex or current) | Metastasis | HRTAs | DDIs | Radiotherapy | Comorbidities |
|---|---|---|---|---|---|---|---|---|---|---|
| Lung | 24.8 | 21.4 | 56.5 | 18.5 | 88.5 | 82.5 | 82.9 | 58.9 | 34.3 | 46.1 |
| Pancreatic | 21.5 | 41.6 | 54.6 | 11.2 | 50.2 | 75.7 | 96.4 | 63.1 | 3.3 | 35.8 |
| Urological | 12.2 | 10.3 | 58.9 | 19.2 | 71.6 | 70.1 | 72.1 | 44 | 19.3 | 53.2 |
| Colorectal | 9.5 | 39.8 | 58.2 | 15.5 | 50.9 | 81.3 | 89.1 | 27.3 | 15.6 | 52.3 |
| Stomach | 7.4 | 29.1 | 60.5 | 11.6 | 62.8 | 74.1 | 91.8 | 40.7 | 10.5 | 47.6 |
| Gynecological | 6.9 | 100 | 55 | 35 | 30 | 71.1 | 87.3 | 71.3 | 5.1 | 46 |
| Breast | 6.1 | 98.5 | 37.1 | 20 | 31.4 | 67.7 | 52.9 | 61.4 | 45.5 | 60.6 |
| Head & neck | 1.3 | 30 | 33.3 | 33.3 | 80 | 63.6 | 80 | 60 | 73.3 | 53.3 |
| Others | 10.3 | 47.3 | 56.3 | 20.2 | 57.1 | 59.6 | 64.4 | 40.3 | 27.4 | 47.9 |